Abstract
The editor’s letter aimed to expose the uncertainties and lack of evidence about the new coronavirus regarding breast-feeding from infected mothers and all possible risks in drug testing trials in the mothers and their infants. From comparisons among scientific studies, it was concluded that the vertical transmission is unlikely, and the benefits of breast-feeding outweigh risks of contamination. In addition, when evaluating the intrinsic properties of each drug, it is concluded that most drugs used in COVID-19 therapy are safe in the lactation period. The only exception was favipiravir since there is no solid information in the literature about its excretion in breast milk.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
